Dysregulation was established for FABP3 in cardiovascular disorders [56, 61], FABP1, FABP2, FABP4 and FABP5 in non-alcoholic fatty liver disease [56, 62] and FABP5 and FABP7 in cancer [56, 63, 64]. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatotic liver disease.